Table 1. Diabetic Nephropathy Stages: Cutoff Values of Urine Albumin for Diagnosis and Main Clinical Characteristics Stages Albuminuria cutoff values (ref. 14) Clinical characteristics (ref. no.) ...

Glomerular hyperfiltration is presumed to be an early event in the development of the nephropathy. Subsequently, microalbuminuria and proteinuria are early clinical markers of the nephropathy.

Atrasentan previously demonstrated efficacy in the open-label AFFINITY basket trial, where it reduced the 24-hour urinary ...

程虹教授：目前，肾科医生对SGLT2抑制剂的肾脏保护作用已经有越来越深的认识，在临床实践中，SGLT2抑制剂可能更多用于非糖尿病的CKD患者，且发挥了非常重要的作用，包括降低蛋白尿、延缓肾病进展。实际上，当RAS抑制剂和SGLT2抑制剂联用时，患者蛋白尿可显著下降 5 。此外，有些患者可能由于血压较低，使用RAS抑制剂会受限，临床可能会选择SGLT2抑制剂来降低蛋白尿，同样也观察到非常好的临床疗效 ...

There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of ...

Felzartamab, an investigational antibody, reduces triggers linked to IgA nephropathy, an autoimmune kidney disease, ...

IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

USA: An interim analysis of the Phase 3 VISIONARY study revealed that sibeprenlimab achieved a significant and clinically ...

Patients with IgA nephropathy and severe proteinuria have a high lifetime risk of kidney failure. The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in ...

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab Felzartamab, an ...